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There is increasing evidence of an inverse association between use of nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of
colorectal cancer. However, data regarding other cancer sites are limited. Using data from the population-based North Jutland
Prescription Database and the Danish Cancer Registry, we compared cancer incidence among 172057 individuals prescribed
nonaspirin NSAIDs with expected incidence (based on county-specific cancer rates) during a 9-year study period. A total of 6081
incident cancer cases were diagnosed among NSAID users vs 5722 expected (standardised incidence ratio (SIR) 1.1, 95% confidence
interval (CI)1.0–1.1). The SIRs for colon and rectal cancer among persons who obtained 10 or more prescriptions were 0.7 (95% CI
0.6–0.9) and 0.6 (95% CI 0.4–0.9), respectively. Similarly, reduced risk estimates were found for stomach (SIR 0.7, 95% CI 0.4–1.1)
and ovarian cancer (SIR 0.7, 95% CI 0.4–1.0). Standardised incidence ratios for other cancers among those with 10 or more
prescriptions tended to be close to 1.0, except for lung, kidney, and prostate cancers with SIRs of 1.3 (95% CI 1.1–1.6), 1.4 (95% CI
0.9–2.1), and 1.6 (95% CI 1.3–2.0), respectively. We found protective associations of NSAIDs against colon, rectal, stomach, and
ovarian cancer. Reasons for the increased risk for some cancer sites are not clear.
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There is substantial evidence of an inverse association between use
of nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of
colorectal cancer (Kune et al, 1988; Rosenberg et al, 1991, 1998;
Thun et al, 1991, 1993; Suh et al, 1993; Muscat et al, 1994; Peleg
et al, 1994; Schreinemachers et al, 1994; Giovannucci et al, 1995;
Smalley et al, 1999; Baron and Sandler, 2000; Coogan et al, 2000;
Langman et al, 2000; Rodrigues and Huerta-Alvarez, 2001). A
protective effect was initially observed in experimental studies and
has been seen in epidemiologic studies of both cohort and case–
control designs. The mechanisms underlying any chemopreventive
effect of NSAIDs are not clear, but inhibition of cyclooxygenase 2
(COX-2) is a prominent candidate (DuBois and Smalley, 1996;
Kawamori et al, 1998; Jones et al, 1999; Morris et al, 2001).
There have been relatively few studies of possible effects of
NSAID use on the risk of other cancers, although protective effects
for oesophageal and stomach cancers have been reported (Thun
et al, 1993; Funkhouser and Sharp, 1995; Garidou et al, 1996;
Farrow et al, 1998). In contrast, a recent study reported an
increased risk of pancreatic and prostate cancer among NSAID
users (Langman et al, 2000). Data regarding the risk of lung,
breast, and ovarian cancer among NSAID users are conflicting
(Peto et al, 1988; Paganini-Hill et al, 1989; Schreinemachers and
Everson, 1994; Egan et al, 1996; Harris et al, 1996, 1999; Cramer
et al, 1998; Akhmedkhanov et al, 2001; Moysich et al, 2001; Meier
et al, 2002).
We have therefore linked the Pharmaco-Epidemiological Pre-
scription Database in North Jutland County and the Danish Cancer
Registry to examine cancer incidence in a large population-based
cohort of NSAID users.
METHODS
The study was carried out within the population of North Jutland,
a Danish county with nearly 500 000 inhabitants. The details of the
study design have been described earlier (Friis et al, 2003). The
county is served by pharmacies equipped with a computerised
accounting system from which data are sent to the Danish National
Health Service, which refunds patients part of the costs associated
with the purchase of drugs, including NSAIDs, prescribed by
doctors, and the prescription data are transferred to the
Pharmaco-Epidemiological Prescription Database (Gaist et al,
1997; Sørensen et al, 2000), including the customer’s unique civil
registry number, the type of drug prescribed (Gaist et al, 1997;
Sørensen et al, 2000), and the date of prescription. The unique civil
registry number ensures that complete individual prescription
histories can be established.
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yThe Prescription Database was used to identify NSAID
prescriptions for 190753 county residents between 1 January
1989 and 31 December 1995. The identified prescriptions were for
the following NSAIDs: azapropazone, diclofenac, etodolac, fenbu-
fen, fenoprofen, flubiprofen, ibuprofen, indomethacin, ketoprofen,
ketorolac, nabumetone, naproxen, phenylbutazone, piroxicam,
proquazon, sulindac, tenoxicam, tiaprofenic acid, tolfenamic acid,
and tolmetin. In Denmark, all NSAIDs can be obtained only by
prescription, except for aspirin and low doses of ibuprofen.
Overall, 7060 (3.7%) of the identified persons prescribed
NSAIDs were excluded from the study cohort because of (i)
residency outside the county of North Jutland at the date of
prescription (n¼6272); (ii) invalid civil registry number (n¼54);
(iii) death prior to or at the date of prescription (n¼55); (iv)
parent (of patient) registered as customer (n¼574); or (v) age
below 16 years (n¼105). After these exclusions, 183 693 (96.3%)
persons were left for subsequent record linkage.
The study cohort was linked to the files of the Danish Cancer
Registry and subjects with a cancer diagnosis, except nonmelano-
ma skin cancer, prior to the date of first recorded prescription for
NSAID (n¼7403; 3.9%) were excluded from the analyses. The
follow-up period began 1 year after the date of the first recorded
NSAID prescription and ended on the date of first primary cancer
diagnosis (except nonmelanoma skin cancer), date of death,
emigration, or 31 December 1997, whichever occurred first. Data
on death for subjects who died during follow-up were obtained
through linkage to the National Mortality Files. To reduce any bias
introduced by the inclusion of patients with recent or undiagnosed
cancer, we excluded the person-time and cancer experience in the
first year of follow-up after the first NSAID prescription, involving
4233 persons (2.2%) who had a cancer diagnosis (n¼1597) or died
(n¼2636) within the first year of follow-up. After these exclusions,
the study cohort included 172057 (90.2%) individuals.
The number of cancer cases observed among users of NSAIDs
was compared with the number expected, based on county-specific
cancer incidence rates from the Danish Cancer Registry. Expected
numbers of first primary cancers in the study cohort were
calculated by multiplying the number of person-years of the cohort
members (in sex groups and 5-year age groups) by the
corresponding 5-year age group and calendar-year-specific in-
cidence rates of first primary cancers for all inhabitants of North
Jutland county who had not received a prescription for an NSAID.
The standardised incidence ratio (SIR) was calculated as the ratio
of the observed to the expected number of cancer cases. We also
computed SIRs stratified by number of prescriptions for NSAIDs.
For these analyses, the person-time experience of the study
subjects was distributed among four categories of prescription
frequency (1; 2–4; 5–9; or X10 prescriptions) with follow-up for
cancer beginning on the date of the first prescription within the
given category. We also performed a test for trend in SIRs with the
number of prescriptions. The statistical methods employed assume
that the observed number of cases of cancer in any specific
category followed a Poisson distribution. We calculated 95%
confidence intervals (CI) for the SIR from an accurate asymptotic
approximation.
RESULTS
Table 1 shows characteristics of the study cohort of 172057
persons free of cancer at the start of follow-up. The mean age at
entry in the study, that is, time of the first recorded prescription
for NSAIDs, was 47.2 years (standard deviation 18.6), and the
mean follow-up after first prescription was 5.4 years (standard
deviation 2.1, range 1–9 years), generating 751182 person-years.
In all, 58% of the study subjects received two or more prescriptions
for NSAIDs during the registration period, with 11% receiving 10
or more prescriptions.
Overall, 6081 incident cancer cases were diagnosed among
NSAID users vs 5722 expected, yielding an SIR of 1.1 (95% CI: 1.0–
1.1) (Table 2). Among the 23 specific types of cancer listed in the
table, the SIRs for all, but five, fell between 0.8 and 1.2. For
gastrointestinal cancers, the SIRs among NSAID users were 0.9
(95% CI 0.8–1.0) for colon cancer, 0.9 (95% CI 0.7–1.0) for
rectum, 0.8 (95% CI 0.6–1.1) for oesophagus, 0.9 (95% CI 0.8–1.1)
for stomach, and 1.1 (95% CI 0.9–1.2) for pancreas cancer.
Increased SIRs were found for cancers of the prostate (SIR, 1.3;
95% CI 1.2–1.5), kidney (SIR 1.2; (95% CI 1.0–1.5), and for
multiple myeloma (SIR, 1.6; 95% CI 1.2–2.0), while a reduced risk
of cervical cancer was seen (SIR, 0.6; 95% CI 0.5–0.8). The results
for site-specific cancers were comparable in men and women (data
not shown).
Table 3 presents results stratified by number of prescriptions for
cancers of the gastrointestinal tract, the sites of a priori interest.
For colon, rectum, and stomach cancers, the lowest SIRs (0.7, (95%
CI 0.6–0.9); 0.6, (95% CI 0.4–0.9) and 0.7, (95% CI 0.4–1.1),
respectively) were found among persons who obtained 10 or more
prescriptions.
Results of similar analyses for other cancer sites are presented in
Table 4. The SIRs for prostate cancer increased with increasing
numbers of prescriptions, with an SIR of 1.6 (95% CI 1.3–2.0)
among those with 10 or more prescriptions. Among persons who
obtained 10 or more prescriptions, the SIR for cancer of the ovary
was decreased (SIR 0.7, 95% CI 0.4–1.0), while for cervical cancer,
there was no evidence of decreasing SIRs with increasing
prescriptions, and for breast cancer the risk estimates were all
close to unity. For lung, bladder, and kidney cancer, we found SIRs
above 1.0 in almost all categories of prescription frequency, with
significant trends for all but bladder cancer. Among persons who
obtained two to four or five to nine prescriptions, the SIRs for
multiple myeloma were increased, although without any obvious
trend with increasing number of prescriptions.
DISCUSSION
In this large population-based follow-up study, we found
significantly reduced risks of colon and rectal cancers, and a
trend towards a reduced risk of stomach cancer among users of
nonaspirin NSAIDs who had filled 10 or more prescriptions.
Overall, we found moderate increased risks of cancers of the
Table 1 Characteristics of 172057 users recorded in the Prescription
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yTable 2 Standardised incidence ratios (SIRs) and 95% confidence intervals (CI) for cancers of selected
sites in users of NSAIDs in North Jutland, Denmark
Cancer site (modified ICD-7 code) Observed SIR 95% CI
All neoplasms 6081 1.1 1.0–1.1
Men 2709 1.1 1.0–1.1
Women 3372 1.1 1.0–1.1
Buccal cavity (140–148) 98 0.9 0.7–1.0
Oesophagus (150) 43 0.8 0.6–1.1
Stomach (151) 131 0.9 0.8–1.1
Colon (153) 427 0.9 0.8–1.0
Rectum (154) 221 0.9 0.7–1.0
Liver (155) 57 1.4 1.0–1.8
Pancreas (157) 149 1.1 0.9–1.2
Lung, primary (162) 692 1.1 1.0–1.2
Breast (170) 696 1.1 1.0–1.2
Ovary (175) 130 0.9 0.7–1.0
Cervix uteri (179) 72 0.6 0.5–0.8
Corpus uteri (172) 148 1.1 0.9–1.3
Prostate (177) 324 1.3 1.2–1.5
Testis (178) 45 1.0 0.7–1.4
Kidney (180) 144 1.2 1.0–1.5
Urinary bladder (181) 330 1.2 1.0–1.3
Melanoma (190) 167 1.0 0.8–1.1
Nonmelanoma skin cancer (191) 1093 1.1 1.0–1.2
Brain (193) 170 1.2 1.0–1.3
Non-Hodgkin’s lymphoma (200, 202) 148 1.1 0.9–1.2
Hodgkin’s disease (201) 23 1.5 0.9–2.2
Multiple myeloma (203) 78 1.6 1.2–2.0
Leukaemia (204) 123 0.9 0.7–1.1
Table 3 Standardised incidence ratios (SIRs) and 95% confidence intervals (CI) for cancers of the
gastrointestinal tract including pancreas, stratified by number of NSAID prescriptions
Cancer site Observed SIR 95% CI
Oesophagus
Number of prescriptions 1 10 0.6 0.3–1.1
2–4 15 0.9 0.5–1.4
5–9 8 0.9 0.4–1.9
X10 10 1.1 0.5–2.0
Test for trend P¼0.21
Stomach
Number of prescriptions 1 35 0.8 0.6–1.1
2–4 58 1.2 0.9–1.6
5–9 20 0.9 0.5–1.3
X10 18 0.7 0.4–1.1
Test for trend P¼0.54
Colon
Number of prescriptions 1 130 0.9 0.8–1.1
2–4 164 1.0 0.9–1.2
5–9 66 0.8 0.6–1.0
X10 67 0.7 0.6–0.9
Test for trend P¼0.05
Rectum
Number of prescriptions 1 67 0.8 0.6–1.0
2–4 86 1.0 0.8–1.2
5–9 38 0.9 0.6–1.2
X10 30 0.6 0.4–0.9
Test for trend P¼0.34
Pancreas
Number of prescriptions 1 30 0.7 0.5–1.0
2–4 58 1.2 0.9–1.6
5–9 37 1.6 1.1–2.2
X10 24 0.9 0.6–1.3
Test for trend P¼0.16
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yprostate and kidney. We did not confirm a reduced risk of lung or
breast cancer as reported in some studies (Schreinemachers and
Everson, 1994; Harris et al, 1996, 1999; Akhmedkhanov et al,
2002). Finally, our data support a reduced risk for ovarian cancer,
which has also been reported among both users of paracetamol
and aspirin (Cramer et al, 1998; Akhmedkhanov et al, 2001), and
we observed a reduced risk of cervical cancer, although not among
those with 10 or more prescriptions. To our knowledge, this
association has not been previously investigated, although an
increase of COX-2 expression has been reported in cervical cancer
(Kulkarni et al, 2001; Sales et al, 2001, 2002).
With few exceptions, studies with different designs and
populations have shown that aspirin and other NSAIDs appear
to decrease the risk of colorectal cancer by up to 50% (Baron and
Sandler, 2000). The consistency of these findings and the biological
mechanisms that appear to explain them (DuBois and Smalley,
1996) suggest that the association is likely to be causal. A similar
protective effect has not been found for paracetamol, further
indicating that the reduced risk is not because of an effect of the
underlying disease (Baron and Sandler, 2000). Some studies
suggest that up to 10–20 years of regular use of NSAIDs is
required before a substantially decreased risk of colorectal cancer
Table 4 Standardised incidence ratios (SIR) and 95% confidence intervals (CI) for selected
nongastrointestinal cancers stratified by number of NSAID prescriptions
Characteristics Observed SIR 95% CI
Lung, primary
Number of prescriptions 1 177 0.9 0.8–1.0
2–4 241 1.1 1.0–1.3
5–9 135 1.4 1.1–1.6
X10 139 1.3 1.1–1.6
Test for trend P¼0.0005˙
Breast
Number of prescriptions 1 193 1.0 0.8–1.1
2–4 258 1.1 1.0–1.3
5–9 120 1.1 0.9–1.3
X10 125 1.1 0.9–1.3
Test for trend P¼0.21
Cervix
Number of prescriptions 1 24 0.6 0.4–0.8
2–4 24 0.6 0.4–0.8
5–9 10 0.6 0.3–1.1
X10 14 0.9 0.5–1.5
Test for trend P¼0.24
Ovary
Number of prescriptions 1 34 0.7 0.5–1.0
2–4 53 1.0 0.8–1.3
5–9 26 1.1 0.7–1.5
X10 17 0.7 0.4–1.0
Test for trend P¼0.99
Prostate
Number of prescriptions 1 87 1.1 0.9–1.4
2–4 105 1.3 1.0–1.5
5–9 61 1.5 1.1–1.9
X10 71 1.6 1.3–2.0
Test for trend P¼0.02
Bladder
Number of prescriptions 1 102 1.1 0.9–1.3
2–4 116 1.2 1.0–1.4
5–9 51 1.1 0.8–1.4
X10 61 1.2 0.9–1.6
Test for trend P¼0.58
Kidney
Number of prescriptions 1 37 1.0 0.7–1.4
2–4 46 1.1 0.8–1.5
5–9 33 1.8 1.2–2.5
X10 28 1.4 0.9–2.1
Test for trend P¼0.04
Multiple myeloma
Number of prescriptions 1 13 0.9 0.5–1.5
2–4 35 2.1 1.4–2.9
5–9 19 2.3 1.4–3.6
X10 11 1.2 0.6–2.2
Test for trend P¼0.28
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ycan be detected (Thun et al, 1993; Giovannucci et al, 1995; Baron
and Sandler, 2000), although others have shown lower rates of
colorectal cancer within 5 years of NSAID use (Smalley et al, 1999;
Rodrigues and Huerta-Alvarez, 2001). An early stage effect appears
likely, especially since aspirin has been associated with a clearly
reduced risk of large-bowel adenomas that are considered a
precursor of most colorectal cancers (Greenberg et al, 1993;
Sandler et al, 1998). However, probably there is a threshold for the
needed dose, since several studies have shown that low-dose
aspirin does not have a major cancer protective effect (Friis et al,
2003).
Our data also add to the literature suggesting that NSAIDs may
exert an antineoplastic effect in the stomach. However, unlike
some previous investigations (Funkhouser and Sharp, 1995;
Garidou et al, 1996; Farrow et al, 1998), we saw no substantial
indication that NSAID use is inversely related to risk of cancer of
the oesophagus.
Previous studies have not indicated a consistent association of
NSAIDs with haematopoietic cancer or cancers of the urinary or
genital tract (Kune et al, 1988; Paganini-Hill et al, 1989; Thun et al,
1993; Baron and Sandler, 2000). Our findings of elevated risks for
cancers of the prostate, kidney, and multiple myeloma among
users of only few prescriptions may indicate that NSAIDs were
prescribed for alleviation of early symptoms of undiagnosed
cancer. Even though we excluded the first year of follow-up, we
may not have avoided this possible confounding by indication, as
some of these cancers may present with long periods with
uncharacteristic symptoms before diagnosis. In addition,
since screening for prostate cancer has increased during the last
decades, surveillance bias may have contributed to the elevated
relative risk estimates for this cancer. One recent study has
suggested that daily use of NSAIDs may be associated with a lower
incidence of prostate cancer (Roberts et al, 2002) in contrast to our
findings and data reported from Great Britain (Langman et al,
2000).
Only phenacetin-containing drugs have been causally linked to
renal cancer (McLaughlin and Lipworth, 2000), but our data
cannot exclude that an association with other NSAIDs may exist.
Since we did not find any strong association between NSAID use
and lung cancer or other smoking-related cancers, it is unlikely
that cigarette smoking is responsible for the observed associations
with kidney cancer (McLaughlin and Lipworth, 2000). Obesity
could be a confounding factor for the latter malignancy, since it is
strongly related to both kidney cancer and osteoarthritis, a
common indication for NSAIDs.
Some studies have examined in detail the risk of lung cancer
among NSAID (primarily aspirin) users. Two follow-up studies did
not find any overall association with aspirin use, but there seemed
to be an inverse association with lung cancer incidence (Paganini-
Hill et al, 1989) and mortality among women (Thun et al, 1993).
Two case–control studies (Rosenberg, 1995; Langman et al, 2000)
reported no association between NSAIDs and lung cancer, but a
third found a relative risk of 0.7 (95% CI 0.3–1.3) among women
taking aspirin for at least 6 months (Akhmedkhanov et al, 2002).
We had no information on cigarette smoking in our population,
and thus we cannot rule out that the small SIR elevations for lung
cancer (similar in men and women) may be because of differential
smoking rates among NSAID users.
The main strengths of our study are its large size, its population-
based design, the completeness of follow-up, and the high quality
of the cancer registration (Storm et al, 1997). The use of a
prescription database eliminates recall bias, which may distort
findings in case–control studies. Unfortunately, we do not have
information on drug use prior to 1989, but large numbers of users
with repeat prescriptions suggest that many subjects were
prevalent users. We also lack clinical details about the indications
for NSAID use and underlying diseases. Another limitation is the
relatively short follow-up period, since long-term use may be
required before a reduced risk of cancer appears (Thun et al, 1993;
Giovannucci et al, 1995; Baron and Sandler, 2000). From another
study, with the aim to study the risk of gastrointestinal bleeding, it
seems that a prescription lasts 60–90 days (Mellemkjaer et al,
2002). In addition, we were unable to control for smoking, dietary
habits, alcohol intake, and other factors. Furthermore, we had no
data on compliance with the prescriptions or use of over-the-
counter NSAIDs. However, the fact that drug exposure was based
on prescriptions actually dispensed at pharmacies and paid in part
by the patients is likely to have improved compliance. In general,
over-the-counter use of nonaspirin NSAIDs in Denmark is 14% of
the total NSAID use (Mellemkjær et al, 2002), but over-the-counter
use may be less common among persons with prescription use, so
possible confounding by over-the-counter use would lead to
underestimation of a reduced cancer risk associated with NSAIDs.
Whatever the impact of these issues, the fact that our estimates for
the effect of NSAID use on risk of colorectal cancer agree closely
with previous findings tends to support the general validity of our
approach.
Our study findings provide further support that NSAIDs may
protect against colorectal and ovarian cancers and perhaps
stomach cancer, in particular, after 10 prescriptions. The increased
risk ratios observed for other cancers need to be investigated
further.
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